Quick answer: Skin diseases are rarely skin diseases — they are systemic metabolic, hormonal, and immune conditions that express themselves on the surface. Acne is driven by insulin-IGF1-mTORC1 signaling; psoriasis is an autoimmune-metabolic syndrome condition linked to the gut microbiome; eczema reflects impaired skin barrier function combined with type 2 immune dysregulation; and rosacea frequently has SIBO and H. pylori as silent upstream drivers. Functional dermatology identifies and corrects these root causes rather than indefinitely suppressing symptoms with topical steroids, antibiotics, or immunosuppressants.
Conventional dermatology has achieved remarkable advances in controlling skin disease — topical retinoids for acne, biologic therapies for psoriasis, dupilumab for eczema. Yet for a large proportion of patients, these treatments manage symptoms without addressing causation, requiring indefinite continuation and producing side effects that range from inconvenient to serious. The functional medicine approach to skin disease starts with the question: what systemic dysfunction is this skin condition expressing?
This article examines the root-cause science behind acne vulgaris, psoriasis, atopic dermatitis, rosacea, androgenic alopecia, and premature skin aging — with a focus on the actionable interventions supported by peer-reviewed evidence.
Acne Vulgaris: The Insulin-IGF1-mTORC1 Disease
Acne vulgaris — affecting approximately 85% of teenagers and a growing proportion of adults — has been understood as a disease of sebaceous gland hyperactivity, follicular keratinization, and Cutibacterium acnes (formerly Propionibacterium acnes) colonization. The functional medicine revision of this model, driven substantially by the work of dermatologist and biochemist Bodo Melnik, positions acne as fundamentally a disease of mTORC1 (mechanistic target of rapamycin complex 1) overactivation in sebocytes — driven by the dietary signaling environment of Western food rather than bacterial colonization per se.
The mechanistic pathway is now well-characterized. Dietary hyperglycemia activates insulin and IGF-1 signaling, both of which activate PI3K-Akt-mTORC1 in sebaceous gland epithelial cells. mTORC1 activation drives sebum overproduction through upregulation of SREBP1 (sterol regulatory element-binding protein 1), increases androgen receptor sensitivity, promotes FoxO1 nuclear exclusion (removing a key anti-proliferative signal), and stimulates keratinocyte proliferation in the follicular infundibulum — every step in the pathological cascade that produces comedones, papules, and pustules.
Melnik’s 2012 synthesis in the Journal of the German Society of Dermatology described acne as a “food-induced mTORC1-driven disease,” supported by the compelling epidemiological observation that populations eating traditional low-glycemic diets (including the Kitavan Islanders studied by Lindeberg and colleagues and the Aché hunter-gatherers studied by Cordain and colleagues, 2002 in the Archives of Dermatology) had essentially zero prevalence of acne — a finding inexplicable by genetics or hygiene, but entirely consistent with the mTORC1 dietary signaling model.
The Low-Glycemic Load Diet RCT Evidence
The critical human RCT evidence for dietary acne treatment came from Smith and colleagues (2007, American Journal of Clinical Nutrition), who randomized 43 young men with acne to either a low-glycemic load diet or a standard Australian diet for 12 weeks. The low-GL group showed a 51% reduction in total acne lesion count versus 32% reduction in the control group — a significant between-group difference — along with significantly greater reductions in androgen levels and SHBG, and greater improvements in insulin sensitivity. The intervention group consumed more protein relative to carbohydrate and lower glycemic index foods; importantly, they maintained the same total caloric intake, confirming the glycemic load mechanism rather than caloric restriction.
Dairy and Acne: Whey Protein and mTORC1
The dairy-acne association has been documented in multiple large epidemiological studies. Adebamowo and colleagues (2005, Journal of the American Academy of Dermatology) analyzed the Nurses’ Health Study II cohort and found that higher total milk consumption in teenage years was associated with significantly increased acne prevalence (OR 1.22 for highest vs. lowest quintile of total milk intake). Skim milk showed the strongest association — paradoxical if fat content were the mechanism, suggesting instead that the bioactive hormones and growth factors (IGF-1, estrogens, progesterone) concentrated in the aqueous fraction drive the effect.
Whey protein — now widely consumed as a protein supplement — is a particularly potent mTORC1 activator because it contains the highest concentration of leucine of any protein source, and leucine directly activates mTORC1 independently of insulin signaling. Multiple case series have documented severe acne exacerbations in athletes consuming whey protein supplements, with resolution upon discontinuation. For acne patients who consume whey protein, switching to plant-based protein sources (pea, hemp, rice) eliminates this specific mTORC1 trigger.
Psoriasis: The Gut Microbiome, Metabolic Syndrome, and Leaky Gut Connection
Psoriasis affects 2–3% of the global population and carries cardiovascular and metabolic comorbidities — metabolic syndrome, non-alcoholic fatty liver disease, inflammatory bowel disease, psoriatic arthritis — that go far beyond the skin. The systemic nature of psoriasis, and its striking comorbidity patterns, reflect shared pathological mechanisms rather than coincidental associations.
The gut-psoriasis connection has been established through multiple lines of evidence. Psoriasis patients show reduced gut microbiome diversity with specific enrichment of Candida species and reduction of Akkermansia muciniphila, Faecalibacterium prausnitzii, and other short-chain fatty acid (SCFA) producers compared to healthy controls — a pattern remarkably similar to the gut microbiome seen in Crohn’s disease. The 2-fold increase in psoriasis prevalence among individuals with inflammatory bowel disease (and vice versa) reflects the shared gut-immune axis pathology: Th17 and IL-23 pathway dysregulation that drives both intestinal and skin inflammation.
Intestinal permeability (“leaky gut”) is measurably elevated in psoriasis patients. Bánvölgyi and colleagues (2019, Frontiers in Immunology) found higher serum zonulin and lipopolysaccharide-binding protein (LBP) in psoriasis patients compared to controls, with zonulin levels correlating with psoriasis disease severity (PASI scores). Circulating LPS from gut bacterial translocation activates TLR4 on keratinocytes and dendritic cells, amplifying the Th17 inflammatory cascade that drives psoriatic plaque formation.
The metabolic syndrome connection is bidirectional and mechanistically coherent: insulin resistance drives chronic inflammation through adipokine dysregulation, NF-κB activation, and elevated TNF-α — the same inflammatory mediator that biologic anti-TNF therapies target in moderate-to-severe psoriasis. Multiple observational studies have shown that weight loss in obese psoriasis patients produces significant PASI score improvements proportional to the degree of weight reduction, independent of medication changes.
The functional medicine approach to psoriasis therefore addresses gut barrier restoration (5R protocol: Remove triggers, Replace enzymes, Reinoculate microbiome, Repair barrier, Rebalance immune system), insulin resistance correction, anti-inflammatory dietary modification, and targeted supplementation — omega-3 fatty acids (Mayser 1998 JAAD RCT: omega-3 infusions 25% improvement vs. omega-6), vitamin D (psoriatic plaques show profound vitamin D receptor dysregulation, and topical vitamin D analogues are first-line conventional therapy), and curcumin (Antiga 2015 BioMed Research International RCT: curcumin 2g/day produced significant plaque area reduction).
Atopic Dermatitis: Skin Barrier, Type 2 Immunity, and the Microbiome
Atopic dermatitis (AD) — eczema — is the most common inflammatory skin disease, affecting 15–20% of children and 7–10% of adults in developed countries, with prevalence rising in tandem with other atopic conditions (asthma, allergic rhinitis, food allergy). The current mechanistic understanding, elegantly reviewed by Weidinger and colleagues in 2018 in the New England Journal of Medicine, posits AD as driven by two converging factors: impaired skin barrier function and type 2 immune dysregulation.
Filaggrin (FLG) gene loss-of-function mutations — present in approximately 30% of European AD patients — impair the formation of the stratum corneum’s natural moisturizing factor (NMF) and reduce intercellular lipid lamellae, creating a “leaky skin barrier” analogous to leaky gut. This allows allergen penetration, microbial dysbiosis, and environmental trigger entry. Staphylococcus aureus colonizes over 90% of AD lesional skin (compared to 5–30% of healthy controls) and is now recognized as an active driver rather than passive opportunist: S. aureus virulence factors (α-toxin, V8 protease, δ-toxin) directly damage the skin barrier, activate TSLP (thymic stromal lymphopoietin) production, and amplify Th2 immune responses. This is why dupilumab (anti-IL-4/IL-13) and newer JAK inhibitors work: they disrupt the type 2 inflammatory loop that maintains S. aureus-favorable skin conditions.
From a functional medicine perspective, the gut-skin microbiome axis is critical in AD. Infants with reduced gut microbiome diversity at 1 month of age — particularly reduced Bifidobacterium and Lactobacillus — have significantly increased risk of developing AD by age 2 (Abrahamsson and colleagues, 2012, Journal of Allergy and Clinical Immunology). Probiotic supplementation in pregnancy and early infancy has been shown in meta-analyses to reduce AD incidence by approximately 22% (Zhu and colleagues, 2021, Nutrients). Lactobacillus rhamnosus GG is the most studied strain, with multiple trials showing significant reductions in SCORAD (SCORing Atopic Dermatitis) indices in established AD. Elimination of identified food triggers (particularly cow’s milk protein and egg white in pediatric AD) produces clinical improvement in documented food-sensitive cases, though indiscriminate food elimination carries risks of nutritional deficiency.
Rosacea: SIBO, H. pylori, and the Gut-Skin Axis
Rosacea — a chronic inflammatory condition causing facial redness, telangiectasias, papules, and in severe cases rhinophyma — is now recognized as having significant gut axis involvement, overturning decades of purely dermatological thinking about this condition.
The SIBO-rosacea connection was established by Parodi and colleagues (2008, Clinical Gastroenterology and Hepatology), who found SIBO by hydrogen breath test in 46% of rosacea patients versus 5% of controls. After triple antibiotic treatment of SIBO, 96% of treated patients showed complete resolution of skin lesions, versus zero in untreated controls — a dramatic finding suggesting that SIBO may be a primary upstream driver of rosacea in a substantial subset of patients. The proposed mechanism involves bacterial translocation of LPS, activation of Toll-like receptor 2 (TLR2, which is massively upregulated in rosacea skin), and cathelicidin (LL-37) dysregulation.
Helicobacter pylori infection has also been associated with rosacea in multiple studies, with H. pylori eradication producing skin improvement in randomized trials. A 2012 meta-analysis by Parodi and colleagues found significantly higher odds of rosacea in H. pylori-positive individuals (OR 3.73, 95% CI 1.65–8.43), and eradication trials showed meaningful rosacea improvement versus placebo. The mechanism may involve H. pylori-produced CagA and VacA toxins driving systemic inflammatory responses that amplify cutaneous TLR2 and cathelicidin pathways. Functional evaluation of rosacea patients therefore routinely includes SIBO breath testing and H. pylori testing (stool antigen or urea breath test) as first-line investigations.
Androgenic Alopecia and Hair Loss: Root Causes Beyond DHT
Androgenic alopecia (AGA) — male-pattern and female-pattern hair loss — is the most common form of hair loss and is driven primarily by dihydrotestosterone (DHT)-mediated miniaturization of hair follicles in genetically susceptible scalp regions. 5-alpha-reductase enzymes (type I and II in the scalp) convert testosterone to DHT, which binds androgen receptors in dermal papilla cells, shortens the anagen (growth) phase, and progressively miniaturizes follicles over years to decades.
However, the purely androgenic model explains only part of the hair loss picture. Functional evaluation systematically investigates non-androgenic contributors that are common, underdiagnosed, and highly treatable: iron deficiency (ferritin <40 ng/mL impairs hair shaft production; optimal ferritin for hair is considered ≥70 ng/mL by many trichologists), thyroid dysfunction (both hypothyroidism and hyperthyroidism cause diffuse telogen effluvium), zinc deficiency, biotin deficiency (rare in those with adequate diet but common in those on long-term PPIs or anticonvulsants), protein insufficiency (hair is the lowest-priority use of dietary protein), vitamin D deficiency (VDR is expressed in hair follicle cells and its activation is required for follicle cycling), and chronic psychological stress (elevated cortisol prematurely pushes follicles into telogen phase, causing diffuse shedding).
For androgenic alopecia specifically, saw palmetto has modest evidence as a 5-alpha-reductase inhibitor. Rossi and colleagues (2012, Journal of the European Academy of Dermatology and Venereology) conducted an RCT comparing saw palmetto 200mg with β-sitosterol versus 1mg finasteride and found that 38% of the saw palmetto group maintained or improved hair scores versus 68% of the finasteride group — meaningful if less potent benefit, without finasteride’s sexual side effect risks. Ketoconazole 2% shampoo has anti-androgenic activity in scalp follicles and multiple trials support its use as an adjunct. Low-level laser therapy (LLLT), via FDA-cleared helmets and combs, has demonstrated modest but statistically significant improvements in hair density in RCTs — the mechanism involving photobiomodulation of cytochrome c oxidase in follicle mitochondria, improving follicular ATP production.
Skin Aging: Glycation, AGEs, and the NRF2 Pathway
The visible aging of skin — wrinkles, loss of elasticity, hyperpigmentation, thinning — reflects multiple converging processes: collagen glycation, UV-induced oxidative damage, declining growth factor signaling, and progressive loss of the skin microbiome diversity that protects barrier function. The functional medicine approach to skin aging addresses modifiable drivers systematically.
Advanced glycation end products (AGEs) — formed when dietary sugars react with proteins and lipids in the Maillard reaction — accumulate in collagen and elastin fibers throughout life, causing crosslinking that stiffens and yellows these structural proteins. The glycation rate is directly proportional to average blood glucose levels over time, which is why diabetics age faster visibly and why reducing dietary glycemic load and optimizing insulin sensitivity has demonstrable anti-aging skin benefits. Dietary AGEs (from high-temperature cooking of animal proteins — charred meats, processed foods) add to the endogenously produced AGE burden. Restriction of dietary AGEs has been shown to reduce serum AGE markers and markers of oxidative stress in clinical studies.
NRF2 — the master transcription factor for antioxidant gene expression — is the most important endogenous defense against skin oxidative aging. NRF2 activators including sulforaphane (broccoli sprouts), curcumin, resveratrol, and astaxanthin activate the antioxidant response element (ARE) to upregulate heme oxygenase-1, glutathione peroxidase, catalase, and other cytoprotective enzymes. Topically applied sulforaphane has been shown to double sunburn cell formation threshold in clinical studies — evidence of meaningful photoprotective NRF2 activation in human skin. Oral astaxanthin (6–12 mg/day) has demonstrated improvements in skin elasticity, moisture, and reduction in fine lines in multiple small RCTs, with the mechanism involving quenching of singlet oxygen and protection of mitochondrial electron transport chain components in dermal fibroblasts.
Collagen supplementation — particularly hydrolyzed collagen peptides (10g/day of specific bioactive tripeptides including Pro-Hyp-Gly) — has moved from cosmetic claim to clinical evidence territory. Proksch and colleagues (2014, Skin Pharmacology and Physiology) conducted an RCT showing significant improvements in skin elasticity and moisture after 8 weeks of collagen peptide supplementation versus placebo. The proposed mechanism involves collagen peptide absorption into circulation and uptake by dermal fibroblasts, stimulating fibroblast collagen synthesis — a positive feedback loop for skin structure maintenance.
Frequently Asked Questions About Functional Dermatology
Can diet really cure acne?
The evidence supports that diet significantly modifies acne severity, though the word “cure” should be reserved for cases where dietary changes produce complete resolution — which does occur in a subset of patients, particularly those with dietary triggers of insulin-IGF1-mTORC1 activation. The Smith 2007 RCT demonstrated 51% reduction in lesion counts on a low-glycemic load diet. Combined elimination of high-glycemic foods, dairy (particularly skim milk and whey protein), and management of underlying insulin resistance produces the most comprehensive dietary impact. Not all acne is equally diet-responsive — hormonal acne driven by PCOS or adrenal androgens may require additional targeted interventions.
What gut testing is useful for chronic skin conditions?
For psoriasis, rosacea, and adult acne, a GI-MAP comprehensive stool test can identify dysbiosis patterns, inflammatory markers (calprotectin), intestinal permeability markers (zonulin), and common pathogens including H. pylori. SIBO breath testing (hydrogen and methane with lactulose or glucose substrate) is particularly relevant for rosacea, given the 46% SIBO prevalence in Parodi’s study. Organic acids testing can identify fungal overgrowth metabolites. For eczema in children, IgE food allergy panel (specific to common triggers: cow’s milk, egg, soy, wheat, peanut, tree nuts) plus an elimination challenge protocol provides the most clinically actionable food sensitivity data.
Is there any evidence that probiotics help skin conditions?
Yes, particularly for atopic dermatitis and acne. The most robust evidence is for Lactobacillus rhamnosus GG and Lactobacillus reuteri in pediatric AD — multiple RCTs and meta-analyses support 20–30% reduction in SCORAD scores. For acne, Lactobacillus acidophilus and L. rhamnosus supplementation showed improvements in acne lesion counts in small RCTs, with mechanisms including reduction in intestinal LPS translocation and modulation of IGF-1 signaling. A probiotic containing Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 demonstrated significant reductions in sebum production and inflammatory acne lesions in a double-blind RCT. The topical probiotic space is also emerging — live commensal bacteria applied to skin can competitively inhibit S. aureus colonization in AD.
Should I take collagen supplements for skin aging?
The evidence for hydrolyzed collagen peptides (10g/day) is becoming increasingly credible, with multiple RCTs now showing improvements in skin elasticity, hydration, and fine lines at 8–12 weeks. The key quality variables are: using specific bioactive peptides (Pro-Hyp-Gly, GPRGF) rather than generic hydrolyzed collagen, vitamin C co-supplementation (required as a cofactor for hydroxylation steps in new collagen synthesis), and sustained daily use. Food sources — bone broth, gelatin, whole fish consumption including skin — provide similar peptides in a food matrix that includes mineral cofactors. The expected effect size is modest (improvement in elasticity, modest reduction in wrinkle depth) — meaningful for skin maintenance but not comparable to topical retinoids or professional procedures.
What is the most evidence-based topical for skin aging?
Topical retinoids (tretinoin, retinol, adapalene) remain the most evidence-backed topical anti-aging intervention, with over 30 years of RCT evidence for increases in dermal collagen, reduction in fine lines, and reversal of UV-induced damage. Vitamin C (L-ascorbic acid, ideally at 10–20% in a pH <3.5 formulation for stability) is the most evidence-supported second-line active, with documented photoprotective, anti-pigmentation, and pro-collagen effects. Niacinamide (vitamin B3, 4–5%) has strong evidence for improving skin barrier function, reducing sebum production, and fading hyperpigmentation — relevant for both aging and acne-prone skin. The functional approach layers these evidence-based topicals with internal nutrition optimization, recognizing that topical application alone cannot compensate for chronic glycation, oxidative stress, and nutritional deficiencies driving dermal matrix degradation from within.
Functional Dermatology: The Comprehensive Skin-Body Assessment
Functional evaluation of skin conditions goes well beyond the skin itself. Laboratory assessment typically includes: complete metabolic panel, fasting insulin and HOMA-IR, complete thyroid panel (TSH, free T3, free T4, anti-TPO), ferritin (optimal 70–100 ng/mL), 25-OH vitamin D, zinc (RBC zinc), complete blood count (rule out deficiency-driven telogen effluvium), hormone panel (testosterone free and total, DHEA-S, estradiol in women), and inflammatory markers (hs-CRP). GI-MAP, SIBO testing, or food sensitivity testing may be added based on the skin condition and clinical history.
Chronic skin conditions are your body communicating that something systemic needs attention. Whether it’s the insulin signaling cascade that drives every comedone, the gut microbiome dysbiosis that drives psoriatic plaque formation, or the SIBO that silently feeds rosacea, the skin is reflecting biology that can be identified, measured, and corrected. To schedule a comprehensive functional dermatology evaluation at The Private Practice, call (810) 206-1402.
Related Articles
- Optimal Vitamin D Levels: What the Research Shows
- Insulin Resistance: Symptoms, Causes & Reversal
- Gut-Brain Axis & Microbiome Mental Health